Whole Cardiac Tissue Bioscaffolds

Tang-Quan, Karis R; Mehta, Nicole A.; Sampaio, Luiz C.; Taylor, Doris A.

doi:10.1007/978-3-319-97421-7_5

Cited by 20 publications

(29 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Synthetic scaffolds are advantageous with respect to the manufacturing process providing reproducible properties such as mechanical strength, size, and configuration 1 . However, current synthetic models are unable to actively respond to cellular signals and often lack the ability to host cell attachment or growth 3,4 . Biologic scaffolds are typically made from purified proteins such as collagen, fibrin, silk, or gelatin 5‐8 .…”

Section: Introductionmentioning

confidence: 99%

Re‐endothelialization of non‐detergent decellularized porcine vessels

et al. 2020

View full text Add to dashboard Cite

The optimal vascular graft should exhibit sufficient mechanical strength, low immunogenicity, high biocompatibility, and resistance to calcification, thrombosis, stenosis, and infection. 1 From a surgical perspective, it should be easy to handle, have reasonable manufacturing costs, and be readily available. Large diameter vascular grafts (>5 mm luminal diameter) have been successfully developed, but smaller vascular grafts (<5 mm luminal diameter) are difficult to generate because of blood clotting, scarring, or occlusion after implantation. 1 The materials used to construct vascular grafts fall into two categories: synthetic or biologic. 2 Synthetic scaffolds are either made from nondegradable polymers such as polytetrafluoroethylene and Dacron, which are widely used in the clinic, or biodegradable polymers such as poly(lactic-acid) and poly(glycolic-acid). 1,2 Synthetic scaffolds are advantageous with respect to the manufacturing process providing reproducible properties such as mechanical strength, size, and configuration. 1 However, current synthetic models are unable to actively respond to cellular signals and often lack the ability to host cell attachment or growth. 3,4 Biologic scaffolds are

show abstract

Section: Introductionmentioning

confidence: 99%

Re‐endothelialization of non‐detergent decellularized porcine vessels

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Scaffold‐based bioinks are characterized by the use of external biomaterials, most commonly hydrogels, which are loaded with cells 35,36 . Examples of previously utilized hydrogels include alginate, fibrin, hyaluronic acid, collagen, and gelatin 37‐39 . The main advantages of using scaffolds are simplicity in creating structures and tremendous scalability.…”

Section: Bioinksmentioning

confidence: 99%

Progress in cardiovascular bioprinting

Quadri

Soman²,

Vijayavenkataraman

2021

Artificial Organs

View full text Add to dashboard Cite

Cardiovascular disease has been the leading cause of death globally for the past 15 years. Following a major cardiac disease episode, the ideal treatment would be the replacement of the damaged tissue, due to the limited regenerative capacity of cardiac tissues. However, we suffer from a chronic organ donor shortage which causes approximately 20 people to die each day waiting to receive an organ. Bioprinting of tissues and organs can potentially alleviate this burden by fabricating low cost tissue and organ replacements for cardiac patients. Clinical adoption of bioprinting in cardiovascular medicine is currently limited by the lack of systematic demonstration of its effectiveness, high costs, and the complexity of the workflow. Here, we give a concise review of progress in cardiovascular bioprinting and its components. We further discuss the challenges and future prospects of cardiovascular bioprinting in clinical applications.

show abstract

“…More recently, the understanding of the native ECM composition and its role in cell behavior has advanced due to decellularization approaches (Crapo et al, 2011). Decellularization techniques aimed to remove all cellular components of an organ or tissue, maintaining the ECM proteins and structure (Crapo et al, 2011; Tang-Quan et al, 2018). This approach leads to distinct possibilities, including the development of new cardiac tissue engineering strategies, through the use of decellularized/recellularized organs in transplants, as well as allowing the characterization of the cardiac ECM in normal or pathological conditions.…”

Section: Exploring the Cardiac Ecm: Composition Tissue Engineering Smentioning

confidence: 99%

“…This approach leads to distinct possibilities, including the development of new cardiac tissue engineering strategies, through the use of decellularized/recellularized organs in transplants, as well as allowing the characterization of the cardiac ECM in normal or pathological conditions. Over the last 10 years, different decellularization and recellularization strategies were developed and performed with murine (Ott et al, 2008; Carvalho et al, 2012; Lu et al, 2013; Wang et al, 2019), porcine (Ott et al, 2008; Weymann et al, 2014; Ferng et al, 2017; Lee P.-F. et al, 2017), bovine (Arslan et al, 2018) and even human (Sánchez et al, 2015; Garreta et al, 2016; Guyette et al, 2016) heart tissue (revised by Scarrit et al, 2015; Tang-Quan et al, 2018).…”

Section: Exploring the Cardiac Ecm: Composition Tissue Engineering Smentioning

confidence: 99%

“…Rat neonatal CM, EC (rat or human origin), hCPC, mesenchymal stem cells (MSC), hPSC and hPSC-CM or hPSC-CPC were some of the cells used for tissue recellularization (Scarrit et al, 2015; Tang-Quan et al, 2018). Using undifferentiated hESC or hESC-derived mesendodermal cells, Ng et al (2011) recellularized mouse hearts and, after 14 days under static culture conditions, cells began to express cardiac markers, such as cTnT, Nkx2.5, Myh6, and others.…”

Section: Exploring the Cardiac Ecm: Composition Tissue Engineering Smentioning

confidence: 99%

See 1 more Smart Citation

Cardiomyogenesis Modeling Using Pluripotent Stem Cells: The Role of Microenvironmental Signaling

Leitolis

Robert

Pereira

et al. 2019

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Pluripotent stem cells (PSC) can be used as a model to study cardiomyogenic differentiation. In vitro modeling can reproduce cardiac development through modulation of some key signaling pathways. Therefore, many studies make use of this strategy to better understand cardiomyogenesis complexity and to determine possible ways to modulate cell fate. However, challenges remain regarding efficiency of differentiation protocols, cardiomyocyte (CM) maturation and therapeutic applications. Considering that the extracellular milieu is crucial for cellular behavior control, cardiac niche studies, such as those identifying secreted molecules from adult or neonatal tissues, allow the identification of extracellular factors that may contribute to CM differentiation and maturation. This review will focus on cardiomyogenesis modeling using PSC and the elements involved in cardiac microenvironmental signaling (the secretome – extracellular vesicles, extracellular matrix and soluble factors) that may contribute to CM specification and maturation.

show abstract

Whole Cardiac Tissue Bioscaffolds

Cited by 20 publications

References 97 publications

Re‐endothelialization of non‐detergent decellularized porcine vessels

Re‐endothelialization of non‐detergent decellularized porcine vessels

Progress in cardiovascular bioprinting

Cardiomyogenesis Modeling Using Pluripotent Stem Cells: The Role of Microenvironmental Signaling

Contact Info

Product

Resources

About